HEMATOLOGIC ONCOLOGY--DRUG DEVELOPMENT AND TESTING

血液肿瘤学项目的总体目标是开发和测试 药物治疗血液肿瘤的新策略和有效策略 剂量密集型方法和生物疗法。 具体目标是： 1.测试治疗非霍奇金氏病的新剂量-强度策略 淋巴瘤和骨髓瘤的生长因子和干细胞支持，以及 监测微小残留病(项目2-1、2-2、2-3)。 2.开发和测试慢性淋巴细胞的治疗意向 白血病与微小残留病的评估(项目2-3)。 3.开发治疗血液肿瘤的新生物疗法(项目2- 7)。 项目2-1重点是克隆型聚合酶链式反应的开发和应用 为了监测最小的残留疾病，项目2-2检查了 干细胞动员治疗复发性淋巴瘤的剂量密集型方法。 项目2-3提出慢性淋巴细胞的治疗意向方案 用聚合酶链式反应测定白血病微小残留病。项目2-4 研究低风险急性髓细胞白血病的治疗方法 联合化疗伴发和集落刺激因子 治疗。项目2-5检查新的化疗和分化 血液肿瘤学的药物。这些项目遵循总体主题 计划项目资助与实体瘤密切结合 肿瘤学课程。

The overall aim of the Hematologic Oncology Project is to develop and test new and effective strategies for treating hematologic neoplasms using dose-intense approaches and biologic therapies. The Specific Aims are: 1. To test novel dose-intense strategies for treating non-Hodgkin's lymphoma and myeloma with growth factor and stem cell support, and monitoring of minimal residual disease (Projects 2-1, 2-2, 2-3). 2. To develop and test a curative intent treatment for chronic lymphocytic leukemia with assessment of minimal residual disease (Project 2-3). 3. To develop new biologic therapies for hematologic neoplasia (Project 2- 7). Project 2-1 focuses on the development and application of a clonotypic PCR for monitoring of minimal residual disease and Project 2-2 examines a dose-intense approach to relapsed lymphoma with stem cell mobilization. Project 2-3 proposes a curative intent protocol for chronic lymphocytic leukemia with PCR determination of minimal residual disease. Project 2-4 examines a therapeutic approach to poor-risk acute myelogenous leukemia integrating chemotherapy concomitant with colony-stimulating factor treatment. Project 2-5 examines new chemotherapeutic and differentiating agents in hematologic oncology. These projects follow the overall themes of the Program Project grant and integrate closely with the Solid Tumor Oncology Program.